A detailed history of Simplex Trading, LLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 4,998 shares of KOD stock, worth $27,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,998
Previous 5,309 5.86%
Holding current value
$27,638
Previous $12,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$2.2 - $3.25 $684 - $1,010
-311 Reduced 5.86%
4,998 $13,000
Q2 2024

Jul 25, 2024

BUY
$2.29 - $4.48 $12,157 - $23,784
5,309 New
5,309 $12,000
Q4 2023

Feb 02, 2024

BUY
$1.4 - $3.24 $3,771 - $8,728
2,694 Added 1333.66%
2,896 $8,000
Q3 2023

Nov 01, 2023

SELL
$1.8 - $7.49 $182,269 - $758,444
-101,261 Reduced 99.8%
202 $0
Q2 2023

Aug 04, 2023

BUY
$4.3 - $9.48 $415,810 - $916,716
96,700 Added 2030.23%
101,463 $700,000
Q1 2023

Apr 27, 2023

BUY
$4.81 - $8.88 $22,910 - $42,295
4,763 New
4,763 $29,000
Q2 2022

Aug 03, 2022

BUY
$5.04 - $9.48 $55,011 - $103,474
10,915 Added 159.74%
17,748 $135,000
Q1 2022

May 02, 2022

BUY
$7.09 - $89.45 $38,909 - $490,901
5,488 Added 408.03%
6,833 $52,000
Q4 2021

Feb 23, 2022

BUY
$80.85 - $128.49 $94,998 - $150,975
1,175 Added 691.18%
1,345 $114,000
Q3 2021

Oct 28, 2021

BUY
$81.97 - $106.94 $8,197 - $10,694
100 Added 142.86%
170 $16,000
Q2 2021

Aug 12, 2021

SELL
$77.2 - $126.54 $1,930 - $3,163
-25 Reduced 26.32%
70 $6,000
Q1 2021

Apr 26, 2021

BUY
$110.45 - $164.47 $3,865 - $5,756
35 Added 58.33%
95 $10,000
Q4 2020

Feb 02, 2021

BUY
$60.78 - $154.03 $3,646 - $9,241
60 New
60 $8,000
Q1 2020

Apr 29, 2020

SELL
$38.18 - $73.95 $6,032 - $11,684
-158 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$13.9 - $76.65 $2,196 - $12,110
158 New
158 $11,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $288M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.